Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bridging study of S12024 in 53 in-patients with Alzheimer's disease.
Allain H, Neuman E, Malbezin M, Salzman V, Guez D, Wesnes K, Gandon JM. Allain H, et al. Among authors: malbezin m. J Am Geriatr Soc. 1997 Jan;45(1):125-6. doi: 10.1111/j.1532-5415.1997.tb01002.x. J Am Geriatr Soc. 1997. PMID: 8994509 Clinical Trial. No abstract available.
Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre M, Sapède C, Moore N; participants of round table N° 5 of Giens Workshops XXVIII (th); Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: malbezin m. Therapie. 2013 Jul-Aug;68(4):241-52. doi: 10.2515/therapie/2013038. Epub 2013 Aug 28. Therapie. 2013. PMID: 23981262 Free article. English, French.
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and OFSEP Investigators. Lebrun-Frénay C, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271. JAMA Netw Open. 2021. PMID: 34633424 Free PMC article.
Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?
Lapeyre-Mestre M, Sapède C, Moore N; les participants à la table ronde N° 5 de Giens XXVIII :; Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: malbezin m. Therapie. 2013 Jul-Aug;68(4):241-6. doi: 10.2515/therapie/2013037. Therapie. 2013. PMID: 27392726 French. No abstract available.
22 results